Does Medicaid cover GLP-1s? It depends which state, and on why

For type 2 diabetes, effectively yes everywhere: state Medicaid programmes must cover FDA-approved drugs for medically accepted indications, so Ozempic and Mounjaro are covered for blood sugar, almost always behind prior authorisation. For obesity it is a patchwork. As of January 2026 only 13 state Medicaid programmes covered GLP-1s for weight under fee-for-service. That is changing: CMS's BALANCE model began rolling out to state Medicaid programmes on 1 May 2026, but joining is voluntary for each state, and Medicaid out-of-pocket costs stay limited to nominal amounts under federal law.

Julian CaraulaniFounder, PriceTracker GLP-1Last checked October 2026

6 min read · published August 2026, updated October 2026

Key takeaways

1For diabetes: covered in every state, because Medicaid must cover FDA-approved drugs for accepted indications.
2For obesity: only 13 state programmes covered GLP-1s under fee-for-service as of January 2026.
3CMS's BALANCE model began rolling out in Medicaid on 1 May 2026; states opt in voluntarily, and out-of-pocket costs stay nominal.
4Prior authorisation is close to universal either way.

Two different answers, and which one you get depends on what the drug is treating and which state you live in.

For type 2 diabetes: effectively yes, everywhere

State Medicaid programmes are required to cover FDA-approved drugs for medically accepted indications. Ozempic and Mounjaro are approved for type 2 diabetes, so for blood sugar they are covered, in every state.

The catch is not whether but how. Coverage comes with utilisation controls, and prior authorisation is close to universal:¹

When covered, GLP-1s are typically subject to utilization controls such as prior authorization, which can further limit access.
KFF

For obesity: a patchwork, and a small one

Weight-loss drugs sit in an optional category for Medicaid, and most states have not taken the option:¹

13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service (FFS) as of January 2026.
KFF, published 16 January 2026

13 states

Covered GLP-1s for obesity under Medicaid fee-for-service as of January 2026. In the other 37, weight was not a route.

What changed in May

CMS built a model called BALANCE to put these drugs inside Medicare and Medicaid on a proper footing. Its Medicaid arm began on 1 May 2026, rolling out state by state through 1 January 2027, and it covers the main GLP-1s by name:²

the following medications will be included: all formulations of Foundayo, Mounjaro, Ozempic, Rybelsus, and Wegovy, and the KwikPen formulation of Zepbound. ... The model will not affect out-of-pocket costs for Medicaid enrollees, which are limited to nominal amounts under federal law.
KFF on BALANCE

The qualifier is the important part:²

Participation in BALANCE is voluntary for drug manufacturers, state Medicaid agencies, and Medicare Part D plans.

In plain English

So your state chooses. A national programme that states opt into is not a national programme yet, and the 13-state figure predates it. If you were told no in 2025, that answer may be out of date, and it is worth asking again.

What to actually do

If you have type 2 diabetes, this is a prior-authorisation conversation, not a coverage one. Your prescriber's office does this routinely.
If weight is the indication, ask your state Medicaid programme directly whether it covers GLP-1s for obesity and whether it has joined BALANCE. Both answers may have changed in 2026.
Do not rely on a manufacturer coupon. Every one of them excludes government beneficiaries, Medicaid included. That route is closed and it is closed on purpose.
Patient assistance is also likely closed to you. Lilly Cares, for instance, requires that you are not enrolled in Medicaid.

If the answer is still no

Then you are in the cash market, and the range is wide:

We priced every route without insurance separately, and the Medicare picture is a different one again: its own arm of BALANCE was delayed, and a temporary manufacturer programme is standing in.

Sources2

KFF, Medicaid coverage of and spending on GLP-1s read August 2026“13 state Medicaid programs covering GLP-1s for obesity treatment under fee-for-service (FFS) as of January 2026. ... When covered, GLP-1s are typically subject to utilization controls such as prior authorization, which can further limit access.” ↩
KFF on the CMS BALANCE model for GLP-1s in Medicare and Medicaid read October 2026“Participation in BALANCE is voluntary for drug manufacturers, state Medicaid agencies, and Medicare Part D plans. ... the following medications will be included: all formulations of Foundayo, Mounjaro, Ozempic, Rybelsus, and Wegovy, and the KwikPen formulation of Zepbound. ... For state Medicaid agencies that opt to participate in the model, implementation will be on a rolling basis from May 1, 2026 through January 1, 2027. ... The model will not affect out-of-pocket costs for Medicaid enrollees, which are limited to nominal amounts under federal law.” ↩

Common questions

Does Medicaid cover Ozempic?

For type 2 diabetes, yes, in every state: Medicaid programmes must cover FDA-approved drugs for medically accepted indications. Prior authorisation is close to universal. For weight loss, coverage is optional for states, and as of January 2026 only 13 state programmes covered GLP-1s for obesity under fee-for-service.

Does Medicaid cover Wegovy for weight loss?

Only in states that have chosen to cover GLP-1s for obesity, which was 13 states as of January 2026. CMS's BALANCE model began rolling out to state Medicaid programmes on 1 May 2026, but participation is voluntary for each state, so the answer still depends on where you live. Where it applies, your out-of-pocket cost stays limited to nominal amounts under federal law.

What is the BALANCE model?

A CMS model covering all formulations of Foundayo, Mounjaro, Ozempic, Rybelsus and Wegovy plus the Zepbound KwikPen. Its Medicaid arm began rolling out on 1 May 2026 and does not change Medicaid out-of-pocket costs, which federal law limits to nominal amounts. Participation is voluntary for drug manufacturers, state Medicaid agencies and Medicare Part D plans.

Can I use an Ozempic or Wegovy coupon if I have Medicaid?

No. Manufacturer savings cards exclude government beneficiaries, which covers Medicaid as well as Medicare. Patient assistance programmes are frequently closed too: Lilly Cares, for example, requires that you are not enrolled in Medicaid, full Low Income Subsidy or VA benefits.

My state said no last year. Is that still true?

Possibly not. The 13-state figure is from January 2026 and the BALANCE model opened to state Medicaid programmes in May 2026, so a state that declined before may have joined since. It is worth asking again rather than assuming.

Choosing a program? See our ranking of the best online GLP-1 programs for every partner side by side, or the cheapest GLP-1 page for price alone.